Clinical Trial Update: CD19/BCMA CAR-T for SLE [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluates a CD19/BCMA CAR-T therapy for systemic lupus erythematosus (SLE). The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CD19/BCMA CAR-T

Snippet

Sponsor: Chengdu Ucello Biotechnology Co., Ltd. | Conditions: SLE - Systemic Lupus Erythematosus | EARLY_Phase 1 | Status: NOT_YET_RECRUITING